Beta Bionics to Host Investor Event on June 22, 2025
Beta Bionics (Nasdaq: BBNX) has announced an upcoming investor event scheduled for June 22, 2025, in Chicago, coinciding with the 85th Scientific Sessions of the American Diabetes Association. The event will run from 7:00 AM to 8:30 AM Central Time.
The presentation will feature:
- Commercial and financial performance updates
- Demonstration of new patch pump development
- Review of adaptive closed-loop algorithm
- Presentation of new real-world clinical data
The event will be accessible via live webcast through the company's investor relations website. In-person attendance requires registration through Beta Bionics' IR representative. A replay of the webcast and presentation materials will be available on the company website after the event.
Beta Bionics (Nasdaq: BBNX) ha annunciato un prossimo evento per investitori programmato per il 22 giugno 2025 a Chicago, in concomitanza con la 85ª Sessione Scientifica dell'American Diabetes Association. L'evento si svolgerà dalle 7:00 alle 8:30 ora centrale.
La presentazione includerà:
- Aggiornamenti sulle performance commerciali e finanziarie
- Dimostrazione dello sviluppo di un nuovo sistema di infusione a cerotto
- Revisione dell'algoritmo adattivo a circuito chiuso
- Presentazione di nuovi dati clinici del mondo reale
L'evento sarà accessibile tramite webcast in diretta attraverso il sito web delle relazioni con gli investitori della società. La partecipazione di persona richiede registrazione tramite il rappresentante IR di Beta Bionics. Una registrazione del webcast e i materiali della presentazione saranno disponibili sul sito web della società dopo l'evento.
Beta Bionics (Nasdaq: BBNX) ha anunciado un próximo evento para inversores programado para el 22 de junio de 2025 en Chicago, coincidiendo con la 85ª Sesión Científica de la Asociación Americana de Diabetes. El evento se llevará a cabo de 7:00 AM a 8:30 AM, hora central.
La presentación incluirá:
- Actualizaciones sobre el rendimiento comercial y financiero
- Demostración del desarrollo de una nueva bomba de parche
- Revisión del algoritmo adaptativo de circuito cerrado
- Presentación de nuevos datos clínicos del mundo real
El evento será accesible a través de una transmisión en vivo a través del sitio web de relaciones con inversores de la compañía. La asistencia en persona requiere registro a través del representante de IR de Beta Bionics. Una repetición de la transmisión y los materiales de la presentación estarán disponibles en el sitio web de la compañía después del evento.
Beta Bionics (Nasdaq: BBNX)는 2025년 6월 22일 시카고에서 열리는 투자자 이벤트를 발표했습니다. 이 행사는 미국 당뇨병 협회의 제85회 과학 세션과 동시에 진행됩니다. 이벤트는 중앙 표준시 기준으로 오전 7시부터 8시 30분까지 진행됩니다.
발표 내용은 다음과 같습니다:
- 상업적 및 재무 성과 업데이트
- 새로운 패치 펌프 개발 시연
- 적응형 폐쇄 루프 알고리즘 검토
- 새로운 실제 임상 데이터 발표
이 이벤트는 회사의 투자자 관계 웹사이트를 통해 실시간 웹캐스트로 접근할 수 있습니다. 대면 참석은 Beta Bionics의 IR 대표를 통해 등록해야 합니다. 이벤트 후 회사 웹사이트에서 웹캐스트 재생 및 발표 자료를 이용할 수 있습니다.
Beta Bionics (Nasdaq: BBNX) a annoncé un prochain événement pour investisseurs prévu le 22 juin 2025 à Chicago, coïncidant avec les 85èmes Sessions Scientifiques de l'American Diabetes Association. L'événement se déroulera de 7h00 à 8h30, heure centrale.
La présentation comprendra :
- Mises à jour sur les performances commerciales et financières
- Démo du développement d'une nouvelle pompe à patch
- Revue de l'algorithme adaptatif en boucle fermée
- Présentation de nouvelles données cliniques du monde réel
L'événement sera accessible par webdiffusion en direct via le site web des relations investisseurs de l'entreprise. La participation en personne nécessite une inscription via le représentant IR de Beta Bionics. Un enregistrement de la webdiffusion et les documents de présentation seront disponibles sur le site web de l'entreprise après l'événement.
Beta Bionics (Nasdaq: BBNX) hat ein bevorstehendes Investoren-Event angekündigt, das für den 22. Juni 2025 in Chicago geplant ist, zeitgleich mit den 85. Wissenschaftlichen Sitzungen der American Diabetes Association. Die Veranstaltung findet von 7:00 bis 8:30 Uhr Central Time statt.
Die Präsentation wird Folgendes umfassen:
- Aktualisierungen zur kommerziellen und finanziellen Leistung
- Demonstration der Entwicklung einer neuen Patch-Pumpe
- Überprüfung des adaptiven Closed-Loop-Algorithmus
- Präsentation neuer klinischer Daten aus der Praxis
Die Veranstaltung ist über einen Live-Webcast auf der Investor-Relations-Website des Unternehmens zugänglich. Die persönliche Teilnahme erfordert eine Registrierung über den IR-Vertreter von Beta Bionics. Eine Aufzeichnung des Webcasts und Präsentationsmaterialien werden nach der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it will host an investor event on Sunday, June 22, 2025, in conjunction with the 85th Scientific Sessions of the American Diabetes Association (ADA) taking place June 20-23, 2025, in Chicago, IL. The event will begin at 7:00 am Central Time (8:00 am Eastern Time) and conclude at approximately 8:30 am Central Time (9:30 am Eastern Time).
Members of the Company’s management team, led by Sean Saint, President and CEO, will present at the event. The agenda will include updates on commercial and financial performance, a demonstration of the patch pump in development, a review of the adaptive closed-loop algorithm, and new real-world clinical data.
The Company invites investors to join the event via live webcast, a link to which will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com. Following the event, a replay of the webcast and its accompanying slide presentation will be archived on the Company’s website.
Investors who would like to attend the event in-person will be required to register, which can be done by contacting the Company’s investor relations representative at ir@betabionics.com.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com
Media and Public Relations:
Karen Hynes
Vice President of Marketing
media@betabionics.com
Source: Beta Bionics, Inc.
FAQ
When and where is the Beta Bionics (BBNX) investor event taking place?
What key topics will be covered at the BBNX June 2025 investor event?
How can investors attend the Beta Bionics (BBNX) June 2025 investor event?
Will there be a replay available of the BBNX June 2025 investor presentation?
